Cetuximab Hypersensitivity in the Setting of Asymptomatic Alpha‐Gal Sensitization
This case suggests caution with the use of cetuximab in those with asymptomatic alpha-gal sensitization, along with the potential utility of graded challenge in a closely monitored setting, such as the ICU, to diagnose and desensitize to manage such patients in the future.
Authors
- Cosby A. Stone (ORCID: https://orcid.org/0000-0002-1888-4188)
- Barbara A. Murphy (ORCID: https://orcid.org/0000-0003-2163-7927)
- Lindsay Mundy
- Alexander G. Emerson
Institutions
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Head & Neck
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1002/hed.70030
- Citations
- 1
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Vanderbilt University
- Agency for Healthcare Research and Quality
- National Institute of Allergy and Infectious Diseases